Physician profile
James C Rieger
NPI 1205828514
$4,048.12
in general payments reported to CMS, 2019-2025
23 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $273 · 2021: $500 · 2022: $1,028 · 2023: $639 · 2024: $311 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $688.93 | 2019-2025 | Cequa |
| Alcon Vision LLC | $686.02 | 2019-2025 | Hydrus Microstent, Clareon, Argos |
| Allergan, INC. | $495.88 | 2019-2021 | |
| Abbvie INC. | $421.76 | 2022-2025 | |
| Oyster Point Pharma, INC. | $315.58 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $290.04 | 2019-2025 | Oxervate |
| Glaukos Corporation | $271.97 | 2022-2024 | Ce-Marked Kxla System |
| Kala Pharmaceuticals, INC. | $265.79 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $101.03 | 2022-2025 | Lotemax Sm, Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.53 | 2019-2021 | |
| Shire North American Group INC | $60.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.67 | 2019-2022 | |
| Coopervision INC. | $58.56 | 2019 | |
| Biotissue Holdings INC. | $43.28 | 2019-2025 | |
| Harrow Eye, LLC | $39.90 | 2024 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $36.45 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $33.94 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $27.31 | 2025 | Xdemvy |
| Amgen INC. | $23.83 | 2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $15.50 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.42 | 2020 | |
| Synergeyes, INC. | $12.84 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $7.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rieger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.